-31.5%
RIVN vs MRNA
+34.8%
-66.3%
-65.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.1% | +5.4% | -5.5% | -0.6% |
| 7D | +1.8% | -1.1% | +2.9% | +1.9% |
| 30D | +0.6% | +126.1% | -125.5% | -14.0% |
| 3M | +3.2% | +190.0% | -186.9% | -16.5% |
| 6M | -3.7% | +157.2% | -161.0% | -20.3% |
| YTD | -18.7% | +388.2% | -406.9% | -42.1% |
| 1Y | +14.7% | +467.0% | -452.3% | -21.6% |
| 3Y | -31.5% | +36.1% | -67.6% | -40.1% |
| All | -31.5% | +34.8% | -66.3% | -40.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling